

Spring To Life™

*The 5th Annual
Spring to Life Conference on Hematologic Malignancies™:
Conference on Indolent Lymphoid Malignancies,
a CE-accredited, 1-day educational conference*

Saturday, May 19, 2018

Healthcare Professional Program – 7:30 AM – 1:15 PM

Patient-Centered Program – 1:30 PM – 3:45 PM

**Albany Marriott Hotel
189 Wolf Road, Albany, NY 12205**

Host

NYOH New York
Oncology
Hematology

Accredited Providers


**LEUKEMIA &
LYMPHOMA
SOCIETY**
fighting blood cancers

**someday
is today**

CEME
Center for Emergency Medical Education

Organized by

**MedEd
Consulting**



AUDIENCE RESPONSE SYSTEM

To interact with the presenters during the conference, please use your mobile device (smartphone, tablet, laptop, etc.) and go to <https://s2l.cnf.io>. The Conferences i/o app will allow you to ask questions as well as respond to polls when they appear on your device.



PRESENTATION DOWNLOAD

The accredited content presented during the conference will be posted online for viewing and download within 7-10 days after the conference. An email will be sent to all participants with viewing and download instructions. Not all presentations will be shared due to reprint and permission restrictions.



INTERNET ACCESS

Complimentary Wi-Fi is available using code “Marriott2018” to log in.



HOW TO CLAIM CREDIT

- Please complete the yellow Continuing Education/Program Evaluation form included in your program packet if you are a physician or allied health professional.
- Please complete the blue Continuing Education/Program Evaluation form included in your program packet if you are a nurse or social worker.
- Return the form to the registration table before leaving today.



Spring To Life™

Dear Healthcare Professional Colleagues:

Welcome to our *Fifth Annual Spring to Life Conference on Hematologic Malignancies*.™ Thank you for choosing to attend to update your knowledge, understanding, and also earn CE credits.

This year's conference is focused on the indolent lymphoid malignancies. The clinician sessions will detail standards of care and emerging strategies for the more common B cell lymphomas (follicular, CLL/SLL and marginal zone), as well as cutaneous T cell lymphoma (CTCL). We have brought together regional expertise with speakers and panelists from New York Oncology Hematology, Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, and Wilmot Cancer Institute of the University of Rochester.

Please join us for our enriching afternoon session with patients, families, and the community, as we continue to share the challenges and lessons of our holistic human experience of living with cancer. This year's focus is *Finding Hope in Times of Transition*. We will have a panel and open discussion with the audience.

Please also take note of our grantors and exhibitors, whose generosity and support are integral to making *Spring to Life* an ongoing reality for our region.


On behalf of our Organizing Committee, thank you again for taking the time out of your lives to join us and enhance your understanding and practice.

Enjoy!

Sincerely,



Ira Zackon, MD, Program Chair
New York Oncology Hematology



Agenda: Healthcare Professional Program

Continuing Education Credit provided for physicians, nurses, and allied health professionals.

7:30 AM - 8:00 AM	Registration, Breakfast, and Exhibits	
8:00 AM - 8:10 AM	Opening Remarks and Pre-Test	Ira Zackon, MD
8:10 AM - 8:30 AM	Marginal Zone Lymphomas	Pooja Chaukiyal, MD
8:30 AM - 8:50 AM	Cutaneous T Cell Lymphoma	Alison Moskowitz, MD
8:50 AM - 9:25 AM	Follicular Lymphoma	Jonathan W. Friedberg, MD
9:25 AM - 9:45 AM	Question and Answer	
9:45 AM - 10:05 AM	Break, Snack, and Exhibits	
10:05 AM - 10:50 AM	KEYNOTE ADDRESS: Chronic Lymphocytic Leukemia (CLL)	Jennifer Brown, MD
10:50 AM - 11:10 AM	Question and Answer	
11:10 AM - 11:55 AM	Case-Based Discussion: Focus on Chronic Lymphocytic Leukemia (CLL)	Faculty Panel
11:55 AM - 12:00 PM	Closing Remarks and Post-Test	Ira Zackon, MD
12:00 PM	Networking	
12:15 PM - 1:15 PM	Non-CME Lunch Session: An Oral Proteasome Inhibitor for Patients with Multiple Myeloma –Tulio E. Rodriguez, MD <i>Director of Blood & Marrow Transplant Program Advocate Lutheran General Hospital, Park Ridge, IL</i>	

Agenda: Patient-, Family-, and Caregiver-Centered Sessions

1:00 PM – 1:30 PM	Patient/Family Registration, Light Lunch, Exhibits	
1:30 PM – 1:40 PM	Opening Remarks	
1:40 PM – 3:40 PM	<i>Finding Hope in Times of Transition</i>	Edward Dick, LCSW Frances Ford, LCSW, Albany NYOH, NY Claire Ralli, LCSW, Clifton Park NYOH, NY
3:40 PM – 3:45 PM	Closing Remarks	
3:45 PM	Adjourn	



Program Description

Spring to Life Conference on Hematologic Malignancies™: Myeloproliferative Neoplasms (MPNs) is an accredited, educational program developed by New York Oncology Hematology (NYOH), in collaboration with the Center for Emergency Medical Education (CEME), the Leukemia & Lymphoma Society, and a panel of expert faculty from the academic, research, and community practice settings.

With programming for both healthcare professionals and the community, the goal of this 1-day activity is to bring together cancer care providers and members of the community—including patients, survivors, their families and caregivers—to gain an up-to-date understanding of blood cancers, including ongoing research, clinical management, and emerging therapies. The program also provides perspectives on the impact of cancer on the lives of patients and families.

The 2018 conference will focus on indolent lymphoid malignancies. Specifically, clinician sessions will detail standards of care and current evidence-based and emerging therapeutics, including efficacy, safety, and tolerability, in order to inform a clinical audience on the more common indolent lymphomas and chronic lymphocytic leukemia.

The theme of the afternoon patient program is *Finding Hope in Times of Transition*.

Healthcare professionals are welcome and encouraged to participate in the afternoon patient-centered sessions.

The morning session will be accredited for continuing education credits for physicians, nurses, and allied health professionals.

Target Audience

The target audience for this conference is hematologists, oncologists, oncology nurses, family and primary care practitioners, allied health professionals, social workers, and any other interested cancer care providers.

Fee Information

There is no fee for this educational activity.

Learning Objectives

Upon completion of this symposium, healthcare professionals should be better able to:


- Identify immunophenotypic and molecular profiling, relevant signaling pathways, and the role of targeted therapies for indolent lymphomas and chronic lymphocytic leukemia
- Review the current standard of care and therapy options for indolent lymphomas and chronic lymphocytic leukemia
- Evaluate the emerging clinical trial data and immunology approaches to the treatment of indolent lymphomas and chronic lymphocytic leukemia
- Demonstrate the clinical application of this information in the common hematology-oncology practice setting

Patient-Centered Sessions

The afternoon segment of this symposium will join patients and their loved ones with national experts, community oncologist/hematologists, and social workers to share stories and improve understanding in an entertaining and supportive environment.

The theme of the 2018 program is *Finding Hope in Times of Transition*.

The unfortunate nature of a cancer diagnosis is that it brings with it an ongoing series of worries and fears as tests and treatments become an integral part of the cancer patient's life. Finding and maintaining a hopeful attitude through these transitions will be the theme of our afternoon program.



Accreditation Statements

Physician and Allied Health Professional Accreditation

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Center for Emergency Medical Education and MedEd Consulting.



The Center for Emergency Medical Education (CEME) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Center for Emergency Medical Education (CEME) designates this live activity for a maximum of 3.75 *AMA PRA Category 1 Credits*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The Center for Emergency Medical Education (CEME) designates this live activity for a maximum of 3.75 hours of participation for continuing education for allied health professionals.

Nurse and Social Worker Accreditation

Approval for nurses has been obtained by the National Office of The Leukemia & Lymphoma Society under Provider Number CEP 5832 to award 3.75 continuing education contact hours through the California Board of Registered Nursing.

Approval for social workers has been obtained by The Leukemia & Lymphoma Society's National Office under provider #1105 to award 3.75 contact hours through the Association of Social Work Boards.

Fair Use Disclosure

- The views and opinions expressed in the presentations, material, and activities on this website and in person are those of the speakers or authors and do not necessarily reflect or represent the views and opinions held by the organizers.
- Due to the nature of the presentations, materials, and activities, the content may contain content copyrighted by another entity or person. The organizers claim no copyright to said content. The organizers cannot be held accountable for the copyrighted content. The organizers are a messenger and sharer of information and strive to verify but cannot warrant the accuracy of copyrights or completeness of the information.
- If you have a complaint or find your content is being used incorrectly, please contact the organizers directly prior to making a copyright claim. Any infringement was not done on purpose and will be rectified to all parties' satisfaction.



Planning Committee

Ira Zackon, MD (Chair)

Medical Hematology and Oncology Director
NYOH Hematology Stem Cell Transplant Program
Hematologist/Oncologist
NYOH, PC
Clinical Assistant Professor
Albany Medical College
Albany, NY

Courtney Bellomo, MD

Hematologist/Oncologist
NYOH Hematology Stem Cell Transplant Program
NYOH, PC
Clinical Assistant Professor
Albany Medical College
Albany, NY

Edward Dick, LCSW

Clinical Social Worker
Hoosick, NY

Mary Jo Tomlinson, RN, BSN, OCN

Stem Cell Transplant
NYOH, PC
Albany, NY

Guest Faculty

Jennifer R. Brown, MD, PhD

Dana-Farber Cancer Institute
Associate Professor, Medicine
Harvard Medical School
Director, CLL Center
Dana-Farber Cancer Institute
Boston, MA

Jonathan W. Friedberg, MD, MMSc

Director, Wilmot Cancer Institute
University of Rochester Medical Center
Rochester, NY

Alison J. Moskowitz, MD

Medical Oncologist
Clinical Director, Lymphoma Inpatient Unit
Memorial Sloan Kettering Cancer Center
New York, NY

Faculty

Ira Zackon, MD (Chair)


Medical Hematology and Oncology Director
NYOH Hematology Stem Cell Transplant Program
Hematologist/Oncologist
NYOH, PC
Clinical Assistant Professor
Albany Medical College
Albany, NY

Courtney Bellomo, MD

Hematologist/Oncologist
NYOH Hematology Stem Cell Transplant Program
NYOH, PC
Clinical Assistant Professor
Albany Medical College
Albany, NY

Pooja Chaukiyal, MD

Hematologist/Oncologist
Director of Plasmapheresis and Transfusion Center
NYOH, PC
Clinical Assistant Professor
Albany Medical College
Albany, NY



Faculty Biographies



Ira Zackon, MD (Chair)

Ira Zackon, MD, is a Hematologist/ Oncologist and Director of the Stem Cell Transplant Program and President of New York Oncology Hematology, PC (NYOH) and assistant clinical professor at Albany Medical College in Albany, New York.

After earning a medical degree in 1986 from McGill University in Montreal, Quebec, Canada, he completed an internship and residency in medicine at Royal Victoria Hospital in Montreal in 1987. Dr. Zackon completed fellowships in Hematology/Medical Oncology at Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire (1990-1992), and Northwestern University Medical Center, Chicago, Illinois (1992-1994).

At NYOH, Dr. Zackon has developed the practice's autologous stem cell transplant program, expanded collaborative care for allogeneic bone marrow transplant patients at NYOH with regional transplant centers, and focused NYOH participation in research trials in the hematologic malignancies through the US Oncology Network and the Blood Cancer Research Partnership in association with the Dana-Farber Cancer Institute in Boston, Massachusetts.



Courtney Belomo, MD


Courtney Bellomo, MD, is a hematologist/oncologist and stem cell transplant physician at New York Oncology Hematology, PC (NYOH) and clinical assistant professor at Albany Medical College in Albany, New York. After earning a medical degree in 2006 from Robert Wood Johnson Medical School in Piscataway, New Jersey, she completed an internal medicine residency and a hematology/oncology fellowship at Robert Wood Johnson University Hospital in New Brunswick, New Jersey. In 2009, she served as chief resident of the internal medicine residency program. She joined the staff at NYOH in August 2013.



Jennifer R. Brown, MD, PhD

Jennifer R. Brown, MD, PhD is the Director of the CLL Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute and an Associate Professor of Medicine at Harvard Medical School in Boston, Massachusetts. Dr. Brown completed a B.S. and M.S. simultaneously in molecular biophysics and biochemistry (MB&B) at Yale, graduating summa cum laude with distinction in MB&B. She proceeded to Harvard Medical School where she received her MD and PhD in molecular genetics in 1998 and was awarded the James Tolbert Shipley Prize for research accomplishment in the graduating class. She then served as an intern and resident in Internal Medicine at Massachusetts General Hospital followed by fellowship in Hematology and Medical Oncology at the Dana-Farber Cancer Institute. Dr. Brown joined the faculty of DFCI and Harvard Medical School in 2004, where she has an active clinical-translational research program in CLL.

Her particular interests include the development of novel targeted therapeutics for CLL, as well as the genomics of CLL. She has been instrumental in the clinical development of both idelalisib and ibrutinib, leading to their regulatory approvals in CLL. In the area of genomics she has been instrumental in the description of the somatic mutation profile of CLL, and is now particularly interested in



the implementation of genomic technology in the clinic, including for prognosis and targeted therapy. She also has a longstanding research interest and focus on the inherited predisposition to CLL. To date she has published over 150 papers in the scientific literature, predominantly in CLL. She is an active member of the CLL Research Consortium and serves on the Alliance Leukemia and Leukemia Correlative Science Committees as well as the NIH Cancer Biomarkers Study Section. In 2014 she was the recipient of two awards from Dana-Farber Cancer Institute, the Clinical Innovation Award, as well as the George Canellos Award for Excellence in Clinical Investigation and Patient Care. She enjoys a worldwide reputation as a CLL expert and is in much demand as an international speaker.



Pooja Chaukiyal, MD

Pooja Chaukiyal, MD, is board-certified in medical oncology and hematology, and currently treats patients at New York Oncology Hematology's Albany Medical Center. Dr. Chaukiyal completed a fellowship in hematology and oncology at the University of Wisconsin. She completed her internal medicine residency at Park Ridge and St. Mary's Hospital in Rochester, New York, and she received her medical degree from University of Pune, India. Dr. Chaukiyal has also practiced in the Veterans Affairs Academic Hospitalist program in Pittsburgh, Pennsylvania, as well as Dean and St. Mary's Hematology Oncology Clinics in Madison, Wisconsin.



Jonathan W. Friedberg, MD, MMSc

Jonathan W. Friedberg, M.D., is Samuel Durand Professor of Medicine at the University of Rochester, and Director of the James P. Wilmot Cancer Institute.

Dr. Friedberg received his medical degree from Harvard Medical School. His postgraduate training included an internship and residency at Massachusetts General Hospital. He also completed a medical oncology and hematology fellowship at Dana-Farber/Partners Cancer Care in Boston. Dr. Friedberg also has an M.M.Sc. degree from Harvard Medical School in clinical investigation.

His research interests focus on development of novel therapies for patients with lymphoma. He is chair of the lymphoma committee in the SWOG NCTN group, and serves as associate editor for hematological malignancies at Journal of Clinical Oncology. He was awarded the Scholar in Clinical Research award from the Leukemia & Lymphoma Society, and has chaired the education program of the American Society of Hematology annual meeting.



Alision J. Moskowitz, MD

Dr. Alision J. Moskowitz received her MD from the Albert Einstein College of Medicine and completed residency in Internal Medicine at Columbia University Medical Center. She trained in Hematology/Oncology at Memorial Sloan Kettering Cancer Center (MSKCC) in New York where she joined the faculty in 2010 as Assistant Attending on the Lymphoma Service. Dr. Moskowitz focuses her clinical practice and research on developing new agents and treatment strategies for patients with T-cell lymphoma and Hodgkin lymphoma. She is the principal investigator and co-principal investigator of multiple clinical trials evaluating targeted agents and new combinations in T-cell lymphoma and Hodgkin lymphoma.



A large white rectangular area with rounded corners, containing 25 horizontal lines for writing.

The Healthcare Professional sessions at the
5th Annual Spring to Life Conference on Hematologic Malignancies™:
Conference on Indolent Lymphoid Malignancies
are supported by educational grants from:

AstraZeneca
Leukemia and Lymphoma Society
New York Oncology Hematology, P.C.

Thank you to the following exhibitors for supporting the
Healthcare Professional sessions at the
5th Annual Spring to Life Conference on Hematologic Malignancies™:
Conference on Indolent Lymphoid Malignancies

GOLD SPONSORSHIP:
Celgene Corporation
New York Oncology and Hematology, P.C.

SILVER SPONSORSHIP:
Pharmacyclics an AbbVie Company

BRONZE SPONSORSHIP:

AbbVie, Inc.	Gilead
Alexion Pharmaceuticals, Inc.	Incyte Corporation
Amgen, Inc.	Janssen Biotech, Inc.
Astellas Pharma US	Leukemia and Lymphoma Society
AstraZeneca	Novartis Oncology
Bristol-Myers Squibb	Pfizer
Boehringer Ingelheim	Sandoz BioPharmaceuticals
Bristol-Myers Squibb	Seattle Genetics, Inc.
Foundation Medicine	Takeda Oncology
Genentech	Teva Pharmaceutical Industries Ltd.

PRODUCT THEATER SPONSORSHIP:
Takeda Oncology

Host



Accredited Providers



**someday
is today**



Organized by

**MedEd
Consulting**

5th Annual Spring to Life Conference on Hematologic Malignancies™:
Conference on Indolent Lymphoid Malignancies
is proudly hosted by New York Oncology Hematology, PC